Terms: = Head and neck cancer AND LIFR, SJS2, 3977, ENSG00000113594, SWS, STWS, CD118 AND Treatment
11 results:
1. Randomized Double-Blind Placebo-Controlled Study of Salivary Substitute with Enzymatic System for Xerostomia in Patients Irradiated in head and neck Region.
Porangaba LP; de Melo Garcia F; Rabelo APAA; Andrade AP; de Abreu Alves F; Pellizzon ACA; Jaguar GC
Curr Oncol; 2024 Feb; 31(2):1102-1112. PubMed ID: 38392076
[TBL] [Abstract] [Full Text] [Related]
2. Adverse health outcomes and global quality of life in long-term testicular cancer survivors: a longitudinal 30-year perspective.
Fosså SD; Haugnes HS; Dahl AA; Kiserud CE; Fosså A; Skalleberg J; Myklebust TÅ
Ann Oncol; 2023 Dec; 34(12):1165-1174. PubMed ID: 37739265
[TBL] [Abstract] [Full Text] [Related]
3. Dosimetric comparison of VMAT standard optimization (SO) and multi-criteria optimization (MCO) treatment plans with standard mode delivery (STD) or sliding window (SW) for head and neck cancer.
Rolland J; Favrel V; Fau P; Mailleux H; Tallet A
J Appl Clin Med Phys; 2023 Sep; 24(9):e14013. PubMed ID: 37144958
[TBL] [Abstract] [Full Text] [Related]
4. Intraglandular Off-the-Shelf Allogeneic Mesenchymal Stem Cell treatment in Patients with Radiation-Induced Xerostomia: A Safety Study (MESRIX-II).
Lynggaard CD; Grønhøj C; Christensen R; Fischer-Nielsen A; Melchiors J; Specht L; Andersen E; Mortensen J; Oturai P; Barfod GH; Haastrup EK; Møller-Hansen M; Haack-Sørensen M; Ekblond A; Kastrup J; Jensen SB; von Buchwald C
Stem Cells Transl Med; 2022 May; 11(5):478-489. PubMed ID: 35435231
[TBL] [Abstract] [Full Text] [Related]
5. Beam complexity and monitor unit efficiency comparison in two different volumetric modulated arc therapy delivery systems using automated planning.
Li C; Tao C; Bai T; Li Z; Tong Y; Zhu J; Yin Y; Lu J
BMC Cancer; 2021 Mar; 21(1):261. PubMed ID: 33691654
[TBL] [Abstract] [Full Text] [Related]
6. [Clinical study on efficacy of nasal surgical expansion as a basic operation in treatment of patients with OSAHS].
Hui P; Xie Y; Ma W; Zhao L; Wang J; Wei X; Zhou L; Xu C; Zhao G; Hou Y
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Nov; 29(21):1860-3. PubMed ID: 26930906
[TBL] [Abstract] [Full Text] [Related]
7. Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance.
Liu SC; Tsang NM; Chiang WC; Chang KP; Hsueh C; Liang Y; Juang JL; Chow KP; Chang YS
J Clin Invest; 2013 Dec; 123(12):5269-83. PubMed ID: 24270418
[TBL] [Abstract] [Full Text] [Related]
8. Does hyperbaric oxygen treatment have the potential to increase salivary flow rate and reduce xerostomia in previously irradiated head and neck cancer patients? A pilot study.
Forner L; Hyldegaard O; von Brockdorff AS; Specht L; Andersen E; Jansen EC; Hillerup S; Nauntofte B; Jensen SB
Oral Oncol; 2011 Jun; 47(6):546-51. PubMed ID: 21493124
[TBL] [Abstract] [Full Text] [Related]
9. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial.
Pow EH; Kwong DL; McMillan AS; Wong MC; Sham JS; Leung LH; Leung WK
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):981-91. PubMed ID: 17145528
[TBL] [Abstract] [Full Text] [Related]
10. Clinical and molecular prognostic factors in operable laryngeal cancer.
Vlachtsis K; Nikolaou A; Markou K; Fountzilas G; Daniilidis I
Eur Arch Otorhinolaryngol; 2005 Nov; 262(11):890-8. PubMed ID: 15739081
[TBL] [Abstract] [Full Text] [Related]
11. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
[TBL] [Abstract] [Full Text] [Related]
